Celularity (CELU) Depreciation & Amortization (CF) (2020 - 2025)
Celularity (CELU) posted quarterly Depreciation & Amortization (CF) of $1.8 million for Q4 2025, down 3.89% year-over-year from $1.9 million in Q4 2024, and down 1.15% quarter-over-quarter from $1.8 million in Q3 2025.
Celularity (CELU) Depreciation & Amortization (CF) (2020 - 2025) Analysis & Trends
Celularity (CELU) has reported Depreciation & Amortization (CF) for 6 consecutive years, with $1.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) fell 3.89% year-over-year to $1.8 million; the TTM figure through Dec 2025 stood at $7.3 million (down 7.91% YoY), while the FY2025 annual figure was $7.3 million, down 7.91% from the prior year.
- Depreciation & Amortization (CF) fell to $1.8 million in Q4 2025 per CELU's latest filing, from $1.8 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $2.6 million in Q4 2021 and bottomed at $1.8 million in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $2.1 million across 5 years, with a median of $2.2 million in 2022.
- Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) surged 55.03% — and 2024, when it decreased 19.16%.
- Celularity's Depreciation & Amortization (CF) stood at $2.6 million in 2021, then retreated by 6.41% to $2.4 million in 2022, then fell by 5.86% to $2.3 million in 2023, then decreased by 18.29% to $1.9 million in 2024, then slipped by 3.89% to $1.8 million in 2025.
- Business Quant data shows CELU's Depreciation & Amortization (CF) at $1.8 million in Q4 2025, $1.8 million in Q3 2025, and $1.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | 1.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.80 Mn |
| Dec 31, 2025 | 1.80 Mn |
| Sep 30, 2025 | 1.82 Mn |
| Sep 30, 2025 | 1.82 Mn |
| Jun 30, 2025 | 1.83 Mn |
| Jun 30, 2025 | 1.83 Mn |
| Mar 31, 2025 | 1.83 Mn |
| Mar 31, 2025 | 1.83 Mn |
| Dec 31, 2024 | 1.88 Mn |
| Dec 31, 2024 | 1.88 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 2.00 Mn |
| Jun 30, 2024 | 2.00 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Dec 31, 2023 | 2.30 Mn |
| Dec 31, 2023 | 2.30 Mn |
| Sep 30, 2023 | 2.34 Mn |
| Sep 30, 2023 | 2.34 Mn |